ストックスクリーナーアプリを入手
104.67
4.12%
-4.50
アフターアワーズ：
104.67
Celcuity Inc (CELC) 最新ニュース
Can Celcuity Inc. stock beat analyst upgradesJuly 2025 Review & Precise Swing Trade Entry Alerts - ulpravda.ru
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech - GlobeNewswire
Is Celcuity Inc. stock attractive after correction2025 Trading Volume Trends & AI Powered Buy and Sell Recommendations - ulpravda.ru
Gains Recap: Can Celcuity Inc stock sustain free cash flow growthMarket Sentiment Review & AI Enhanced Market Trend Forecasts - moha.gov.vn
What valuation multiples suggest for Celcuity Inc. stockMean Reversion Trades & Exceptional Profit Growth - ulpravda.ru
Celcuity initiated with an Outperform at Wolfe Research - MSN
Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase? - The Globe and Mail
Analysts Expect Breakeven For Celcuity Inc. (NASDAQ:CELC) Before Long - 富途牛牛
Celcuity (CELC) surges 662% in 2025 on breast cancer treatment trial results - MSN
What analysts say about Celcuity Inc stockWeekly Market Snapshot & You’ll Thank Yourself in 6 Months - earlytimes.in
Celcuity (CELC) Surges 662% in 2025 on Breast Cancer Treatment Trial Results - Insider Monkey
Meet the 10 Market Stars Behind Millionaire-Making in 2025 - Insider Monkey
2025’s best-performing Minnesota public company stock is a biopharmaceutical firm with no revenue - Star Tribune
Celcuity, Inc. (NASDAQ:CELC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Trading Systems Reacting to (CELC) Volatility - Stock Traders Daily
Celcuity: After Stellar 2025, I Predict More Success In 2026 And Beyond (NASDAQ:CELC) - Seeking Alpha
Celcuity (CELC)’s Clinical Success and M&A Potential Underpin Wolfe Research’s Bullish View - MSN
Celcuity Inc. Earnings Call: Strong Progress Amid Challenges - MSN
Net current asset value per share of Celcuity Inc. – GETTEX:7VR - TradingView — Track All Markets
ETFs Investing in Celcuity Inc. Stocks - TradingView — Track All Markets
Top Biotech Stocks To Add to Your WatchlistDecember 20th - MarketBeat
Does Celcuity Inc. stock trade at a discount to peersJuly 2025 Short Interest & Risk Managed Investment Signals - Улправда
Celcuity (CELC): Reassessing Valuation After New VIKTORIA-1 Breast Cancer Data Boosts Investor Interest - Sahm
Rate Hike: Why Celcuity Inc. stock could be next big winnerMarket Growth Report & Advanced Technical Analysis Signals - Улправда
How Celcuity Inc. stock reacts to job market dataBear Alert & AI Enhanced Trading Alerts - ulpravda.ru
Why Celcuity Inc. stock is trending among retail traders2025 Valuation Update & Scalable Portfolio Growth Ideas - ulpravda.ru
Aug Retail: How Celcuity Inc. stock reacts to job market dataJuly 2025 Big Picture & Entry Point Strategy Guides - Улправда
(CELC) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Will Celcuity Inc. stock deliver better than expected guidanceIPO Watch & Stepwise Trade Execution Plans - Bölüm Sonu Canavarı
Why Celcuity Inc. stock is a value investor pickJuly 2025 Opening Moves & Risk Managed Investment Strategies - DonanımHaber
How interest rate cuts could boost Celcuity Inc. stockMarket Weekly Review & Growth Focused Stock Reports - DonanımHaber
Rate Cut: Why Celcuity Inc. stock could be next big winnerJuly 2025 Big Picture & AI Powered Market Trend Analysis - Улправда
Why Celcuity Inc. stock is rated strong buyTrade Performance Summary & Risk Managed Investment Entry Signals - ulpravda.ru
Aug Final Week: Why Celcuity Inc. stock could be next big winnerWeekly Trade Report & Free Low Drawdown Momentum Trade Ideas - ulpravda.ru
Fundamentals Check: Does Celcuity Inc. stock trade at a discount to peersMarket Sentiment Summary & Weekly Top Gainers Alerts - Улправда
Why Celcuity Inc. stock could be next big winnerMarket Sentiment Report & Fast Gaining Stock Reports - Улправда
Aug Sectors: How Celcuity Inc. stock reacts to job market dataJuly 2025 Analyst Calls & Long-Term Capital Growth Ideas - Улправда
How Investors Are Reacting To Celcuity (CELC) Gedatolisib’s Phase 3 Breast Cancer Data And Safety Profile - Yahoo Finance
Leerink Partners raises Celcuity stock price target to $118 on gedatolisib outlook - Investing.com Nigeria
Leerink Partners raises Celcuity stock price target to $118 on gedatolisib outlook By Investing.com - Investing.com South Africa
Celcuity (CELC): Fresh Phase 3 Breast Cancer Data Prompts Closer Look at Gedatolisib-Driven Valuation - Yahoo Finance
Did Gedatolisib’s Phase 3 PFS and Tolerability Data Just Shift Celcuity’s (CELC) Investment Narrative? - simplywall.st
Celcuity (NASDAQ:CELC) Coverage Initiated by Analysts at Wells Fargo & Company - MarketBeat
Celcuity initiated with an overweight at Wells Fargo - MSN
Celcuity (CELC) Valuation Check After Paradigm-Shifting VIKTORIA-1 Breast Cancer Data Update - Sahm
Celcuity (NASDAQ:CELC) Hits New 1-Year HighShould You Buy? - MarketBeat
Eventide Asset Management LLC Buys 123,774 Shares of Celcuity, Inc. $CELC - MarketBeat
Wells Fargo Initiates Coverage of Celcuity (CELC) with Overweight Recommendation - Nasdaq
Is CELC Stock Overpriced? - timothysykes.com
RH Posts Strong Q3 Sales, Joins Canopy Growth, Tilray Brands, Frequency Electronics And Other Big Stocks Moving Higher On Friday - Benzinga
Celcuity stock hits all-time high at 109.15 USD By Investing.com - Investing.com Canada
Celcuity stock hits all-time high at 109.15 USD - Investing.com
Celcuity downgraded to Neutral from Buy at H.C. Wainwright - MSN
Wells Fargo Initiates Celcuity With Overweight Rating, $126 Price Target - marketscreener.com
Celcuity Inc. (CELC)’s FDA NDA for Gedatolisib Accepted Under RTOR, Accelerating Review - MSN
0.80%
4.56%
大文字化:
|
ボリューム (24 時間):